Rhumbline Advisers Has $745,000 Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Rhumbline Advisers increased its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 1.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,715 shares of the biotechnology company’s stock after purchasing an additional 525 shares during the period. Rhumbline Advisers owned approximately 0.11% of AnaptysBio worth $745,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Trexquant Investment LP increased its holdings in shares of AnaptysBio by 107.6% during the fourth quarter. Trexquant Investment LP now owns 21,832 shares of the biotechnology company’s stock worth $468,000 after buying an additional 11,318 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of AnaptysBio during the fourth quarter worth approximately $119,000. Franklin Resources Inc. increased its holdings in shares of AnaptysBio by 22.7% during the fourth quarter. Franklin Resources Inc. now owns 405,115 shares of the biotechnology company’s stock worth $8,678,000 after buying an additional 75,025 shares in the last quarter. First Light Asset Management LLC increased its holdings in shares of AnaptysBio by 56.4% during the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after buying an additional 446,372 shares in the last quarter. Finally, Great Point Partners LLC increased its holdings in shares of AnaptysBio by 9.2% during the fourth quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock worth $20,927,000 after buying an additional 82,648 shares in the last quarter.

AnaptysBio Stock Performance

Shares of ANAB stock opened at $35.57 on Tuesday. The firm’s 50 day moving average price is $35.79 and its two-hundred day moving average price is $27.95. AnaptysBio, Inc. has a 52-week low of $13.36 and a 52-week high of $41.31. The stock has a market cap of $971.74 million, a PE ratio of -5.79 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $10.97 million during the quarter, compared to the consensus estimate of $25.85 million. As a group, sell-side analysts predict that AnaptysBio, Inc. will post -6.84 earnings per share for the current fiscal year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares in the company, valued at $189,333.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were purchased at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the purchase, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at approximately $189,333.04. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,440 shares of company stock worth $1,193,831. 33.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Truist Financial raised their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Finally, HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a research note on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and a consensus price target of $50.30.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.